Core Insights - Chewy Inc. is set to release its first-quarter fiscal 2025 earnings results on June 11, with investors contemplating whether to buy or hold the stock [1] Group 1: Company Performance and Expectations - Chewy has established a strong presence in the online pet retail market, focusing on innovation and customer loyalty, which positions the company for long-term growth [2] - The Zacks Consensus Estimate for first-quarter revenues is $3.08 billion, reflecting a 6.9% increase from the previous year, while the earnings estimate remains at 34 cents per share, indicating a 9.7% year-over-year rise [3][8] - Chewy has a trailing four-quarter earnings surprise of 19.3%, with the last quarter surpassing the Zacks Consensus Estimate by 33.3% [4] Group 2: Key Growth Drivers - The growth in Chewy's revenue is supported by its Autoship program, which encourages repeat purchases and stabilizes revenue streams [10] - Active customer growth is a positive indicator, with the Zacks Consensus Estimate suggesting an increase to 20.5 million active customers, driven by improved digital experiences and the Chewy+ Membership Program [11] - Chewy's expansion into higher-margin areas, such as its in-house ad platform and veterinary services, is enhancing customer acquisition and engagement [12] Group 3: Market Position and Valuation - Chewy's stock has increased by 22.1% over the past month, outperforming the industry average of 1.2% [13] - The company trades at a forward 12-month price-to-sales (P/S) ratio of 1.57, which is lower than the industry average of 2.00, indicating a favorable investment opportunity [16] - Chewy's valuation is higher than competitors like Central Garden & Pet Company, Petco Health and Wellness Company, and BARK, which have lower P/S ratios [17] Group 4: Investment Considerations - Chewy's investments in automation, advertising, and veterinary services reflect a commitment to long-term growth, although the lack of a clear earnings beat signal may lead to cautious investment decisions [19]

Key Takeaways CRWD shares have jumped 51.7% in 3 months, outpacing peers like CYBR, PANW, and CHKP. Falcon Flex adoption hit $3.2B in deal value, with over 820 customer accounts using the model. CRWD's costs surged in Q1, contributing to a 7.6% drop in non-GAAP earnings.CrowdStrike Holdings (CRWD) shares have soared 51.7% over the past three months, outperforming the Zacks Security industry’s 23.5% growth. The stock has also exceeded the returns of other industry peers, including CyberArk Software (CYBR) ...

Byrna Technologies Inc. (BYRN) shares ended the last trading session 18% higher at $31.35. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 17.4% gain over the past four weeks.The stock is benefitting from the record-setting revenue expectation announced during the company’s 2Q25 preliminary results. These record quarterly revenues mark a 41% y/y increase.This company is expected to post quarterly earnings of $0.04 ...

Media & entertainment stock Warner Bros Discovery Inc (NASDAQ:WBD) was last seen up 10.1% at $10.81, after the company announced it will split into two publicly traded companies by next year. CEO David Zaslav will head the streaming and studios company, which will contain HBO Max, while CFO Gunnar Wiedenfels will become CEO of the global networks business, which includes CNN, TNT Sports, and Discovery.Today's pop has Warner Bros stock breaking above recent pressure at $10, trading at its highest level since ...

Shares of Alvotech (ALVO) have gained 10.1% over the past four weeks to close the last trading session at $10.66, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $18.40 indicates a potential upside of 72.6%.The average comprises five short-term price targets ranging from a low of $14 to a high of $28, with a standard deviation of $5.73. While the lowest estimate indicates an inc ...

Shares of Apogee Therapeutics Inc. (APGE) have gained 9.9% over the past four weeks to close the last trading session at $40.98, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $93.88 indicates a potential upside of 129.1%.The average comprises eight short-term price targets ranging from a low of $78 to a high of $116, with a standard deviation of $11.05. While the lowest estima ...

Shares of Concentra Group (CON) have gained 2.9% over the past four weeks to close the last trading session at $22.03, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $28 indicates a potential upside of 27.1%.The average comprises eight short-term price targets ranging from a low of $25 to a high of $30, with a standard deviation of $1.85. While the lowest estimate indicates an ...

Shares of BILL Holdings (BILL) have gained 2% over the past four weeks to close the last trading session at $45.62, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $66.75 indicates a potential upside of 46.3%.The average comprises 24 short-term price targets ranging from a low of $40 to a high of $120, with a standard deviation of $20.19. While the lowest estimate indicates a de ...

Shares of Birkenstock (BIRK) have gained 4.1% over the past four weeks to close the last trading session at $54.76, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $68.88 indicates a potential upside of 25.8%.The average comprises 17 short-term price targets ranging from a low of $57 to a high of $81, with a standard deviation of $7.34. While the lowest estimate indicates an inc ...

Shares of Monte Rosa Therapeutics (GLUE) have gained 22.5% over the past four weeks to close the last trading session at $5.01, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $16.14 indicates a potential upside of 222.2%.The mean estimate comprises seven short-term price targets with a standard deviation of $3.98. While the lowest estimate of $10 indicates a 99.6% increase from ...